Meeting
2021 ASCO Annual Meeting
Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.
Authors
Alison M. Schram
Memorial Sloan Kettering Cancer Center, New York, NY
Alison M. Schram , Jordi Rodon Ahnert , Manish R. Patel , Shekeab Jauhari , Jasgit C. Sachdev , Viola Weijia Zhu , Patricia LoRusso , Danny Nguyen , Xiuning Le , Matthew O'Connor , Nigel Waters , Carl Cook , Karsten Witt , Rachel W. Humphrey , Pasi A. Janne , Erika P. Hamilton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT04209465
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3086)
DOI
10.1200/JCO.2021.39.15_suppl.3086
Abstract #
3086
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies.
First Author: Erika Paige Hamilton
Poster
2020 ASCO Virtual Scientific Program
Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).
First Author: Milind M. Javle
Poster
2024 ASCO Annual Meeting
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.
First Author: Cristina Saura
Poster
2023 ASCO Annual Meeting
Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.
First Author: Sarina A. Piha-Paul